Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) shares saw unusually-high trading volume on Tuesday . Approximately 413,006 shares traded hands during mid-day trading, an increase of 5% from the previous session’s volume of 395,039 shares.The stock last traded at $38.0650 and had previously closed at $38.86.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on PHVS. New Street Research set a $60.00 price objective on shares of Pharvaris in a report on Friday, August 14th. Citigroup reaffirmed a “market outperform” rating on shares of Pharvaris in a report on Wednesday, September 9th. Leerink Partners boosted their price objective on Pharvaris from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 9th. Guggenheim increased their target price on Pharvaris from $40.00 to $44.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Finally, HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Pharvaris in a research note on Tuesday, September 8th. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $59.87.
Get Our Latest Stock Report on Pharvaris
Pharvaris Stock Performance
Pharvaris (NASDAQ:PHVS – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). As a group, research analysts forecast that Pharvaris N.V. will post -3.12 EPS for the current year.
Insider Activity at Pharvaris
In other news, insider Anne Lesage sold 30,703 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total value of $1,089,649.47. Following the transaction, the insider owned 93,969 shares of the company’s stock, valued at approximately $3,334,959.81. This trade represents a 24.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of Pharvaris stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the sale, the director owned 315,167 shares of the company’s stock, valued at approximately $11,185,276.83. This represents a 8.88% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 169,364 shares of company stock worth $6,176,421.
Institutional Trading of Pharvaris
A number of institutional investors have recently bought and sold shares of PHVS. venBio Partners LLC acquired a new position in shares of Pharvaris during the 2nd quarter worth about $160,569,809. Wellington Management Group LLP raised its position in Pharvaris by 12.9% in the 2nd quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock valued at $82,748,000 after buying an additional 274,034 shares during the last quarter. Commodore Capital LP lifted its stake in Pharvaris by 1.6% in the 1st quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock valued at $54,211,000 after acquiring an additional 29,525 shares in the last quarter. 5AM Venture Management LLC acquired a new position in Pharvaris during the 2nd quarter worth approximately $27,581,008. Finally, Seven Fleet Capital Management LP boosted its position in Pharvaris by 144.6% during the 2nd quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock worth $26,782,000 after acquiring an additional 457,804 shares during the last quarter.
About Pharvaris
Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.
Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.
Featured Articles
- Five stocks we like better than Pharvaris
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
- Cashing in on the Qubit: NVIDIA Takes the Quantum Leap
- Ready to Rumble: Anthropic Rings the AI Bell
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
